SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending following a positive earnings report and increased guidance, sparking excitement about its potential in the AI data center space. The community is actively discussing the possibility of a short squeeze and future hyperscaler deals, while some caution against overvaluation and potential algorithmic selling. Despite differing opinions, bullish sentiment appears to be dominating the conversation surrounding APLD.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending as traders eye a potential breakout, fueled by optimism around AI and cloud growth. Community members are actively discussing short-term price movements and potential options plays, with some anticipating a run towards higher price targets. Despite some bearish sentiment and concerns about lagging performance, many bulls believe AMZN is undervalued and poised to catch up with its mega-cap peers.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp ($LAES) is trending due to its partnership to develop quantum-resistant chips for U.S. defense, fueling speculation of government contracts and a potential short squeeze. The community is comparing it to other quantum stocks like $IONQ and $RGTI, with many believing it's undervalued and poised for significant growth. Discussions also highlight upcoming catalysts, including a satellite launch and the release of a new chip.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending as community members discuss its potential for a short squeeze, fueled by high short interest and significant call option volume at the $20 strike. Some investors believe the stock is undervalued compared to peers and are drawing comparisons to Palantir's early growth, citing UiPath's shift towards AI and partnerships with major tech companies as catalysts for future gains. Others are focused on technical analysis, highlighting breakout potential and resistance levels.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf (WULF) is trending as the community discusses its potential to catch up with sector peers like APLD and IREN, particularly due to its increasing focus on AI and high-performance computing data centers. Discussions revolve around a possible short squeeze, fueled by high short interest and a large amount of call options, with some speculating on price targets and the impact of upcoming earnings and potential catalysts like the Cayuga site approval. Some investors point to the backing of Google as a catalyst for growth.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending due to the upcoming merger with Terra Innovatum, with the ticker symbol slated to change to NKLR, a catchy name in the nuclear sector; the merger vote is scheduled for early October. The community is excited about the ticker change and is comparing the company to sector peers, anticipating a significant rise in valuation post-merger, although some caution about potential volatility.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as community members speculate about potential ETF approvals and discuss the possibility of a breakout from its multi-year consolidation pattern. Some believe LTC is undervalued compared to other cryptocurrencies, while others point to its technical indicators as a sign of an impending rally. The conversation is fueled by anticipation and debate over its future performance.

Siyata Mobile, Inc. engages in the provision of cellular communications systems for enterprise customers. It specializes in connected vehicle products for professional fleets, marketed under the Uniden Cellular and Siyata brands. The firm operates through the following geographical segments: Europe, the Middle East and Africa; Unites States; Canada; and Australia and New Zealand. The company was founded by Marc Seelenfreund on October 15, 1986 and is headquartered in Montreal, Canada.

Core AI Holdings Inc.

Core AI Holdings, Inc.

Core AI Holdings ($CHAI) is trending as investors express frustration and confusion following its NASDAQ debut after a reverse merger, citing a lack of communication and disappointing price action; the community is actively discussing concerns around financials, the merger's purpose, and potential short attacks, while also questioning the company's strategy. Some are hopeful for a turnaround pending news and brokerages resolving trading issues, while others voice deep skepticism and regret, comparing it to past disappointments.

One and one Green Technologies. Inc - Ordinary Shares - Class A

One and one Green Technologies ($YDDL) is trending following its IPO, with significant after-hours volatility and considerable interest due to its low float. Community members are actively discussing potential overnight holds, possible price targets, and the company's business model as a waste management and scrap metal recycling company in the Philippines. Many are also comparing it to other recent IPOs with similar price action.

The Hershey Co. engages in the manufacture and marketing of chocolate, sweets, mints and confectionery products. The firm operates through the following segments: North America Confectionery, North America Salty Snacks and International. The North America Confectionery segment is responsible for the traditional chocolate and non-chocolate confectionery market position of the company, as well as its grocery and snacks market positions, in the United States and Canada. The North America Salty Snacks segment is responsible for the salty snack products in the United States. The International segment includes the combination of all other operating segments, including those geographic regions where the company operates outside of North America. Its brands include Hershey's, Reese's, and Kisses. The company was founded by Milton S. Hershey in 1894 and is headquartered in Hershey, PA.

Hershey Company

Hershey is trending amid speculation of a potential acquisition by Mondelez, driving significant price movement. Community discussions revolve around the likelihood of the deal given Hershey's trust structure and previous rejections, as well as the potential impact of cocoa prices and consumer demand on a combined entity. Analysts are weighing in on the potential valuation and strategic fit within the broader food and beverage sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Philip Morris International Inc. (PM) said on Wednesday that its experts met with the Tobacco Products Scientific Advisory Committee on October 7 as it seeks to continue marketing versions of its IQOS heated tobacco products in the U.S. as modified risk tobacco products.The committee provides nonbinding recommendations to the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP). The modified risk tobacco product designation granted by the FDA initially in 2020 allowed the company to advertise its perks, including that the IQOS system heats tobacco instead of burning it, significantly reducing the production of and users’ exposure to harmful chemicals.PMI has requested that it be allowed to continue marketing versions of IQOS as modified risk tobacco products.“We encourage the FDA to continue efforts to establish a timely scientific review process for smoke-free products—including for IQOS ILUMA, which has been pending FDA review for nearly two years and has globally shown even higher rates of legal-age adults fully switching from combustible cigarettes—that are a better choice for legal-age adults who would otherwise use traditional tobacco products, including combustible cigarettes,” PMI U.S. CEO Stacey Kennedy <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251008608945/en/Philip-Morris-International-Urges-U.S.-Food-and-Drug-Administration-Advisory-Committee-to-Recommend-Continued-Marketing-of-IQOS-as-Modified-Risk-Product">said</a>.The company estimates that there are approximately 34 million IQOS consumers globally who have moved away from cigarettes or significantly reduced their consumption as of June 30. PMI first entered the U.S. market in 2022, following its acquisition of Swedish Match.On Stocktwits, retail sentiment around PM stock fell from 'extremely bullish' to 'bullish' territory over the past 24 hours, while message volume stayed at 'high' levels.&nbsp;<a href="https://stocktwits.com/symbol/PM">PM stock</a> is up by 28% this year and by 30% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-faces-1-billion-hit-after-new-york-aluminum-plant-fire-analysts-say/ch6EZaVR3iF">Ford Faces Up To $1 Billion Hit After New York Aluminum Plant Fire, Analysts Reportedly Say</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Philip Morris International Inc. is displayed on a smartphone screen, with the company's branding in the background, on April 20, 2025, in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Philip Morris Seeks FDA Approval To Keep IQOS Modified Risk Designation For Later Versions Of Device

The modified risk tobacco product designation granted by the FDA initially in 2020 allowed the company to advertise IQOS’ perks. 

Equity

Shares of CarMax (KMX) slumped 24% on Thursday morning after the company’s second-quarter earnings fell below Wall Street expectations, sparking a downgrade by Wedbush.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://media.carmax.com/press-releases/news-release/2025/CarMax-Reports-Second-Quarter-Fiscal-Year-2026-Results/default.aspx">Total vehicle sales</a> for the company declined 4.1% year-over-year in the quarter to 338,031 units, resulting in a 6% decrease in revenue to $6.59 billion, which fell short of the estimated $7.02 billion. Net earnings per share came in at $0.64, down from $0.85 in the corresponding quarter of 2024.Total net income declined 28% to $95.4 million, while income from the company’s auto finance business fell 11.2% to $102.6 million. The company pinned the drop in income from the auto finance segment to an increase in the provision for loan losses, which outweighed growth in net interest margin.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KMX">KMX stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.CEO Bill Nash admitted that the quarter was “challenging,” but said the used auto retailer remains confident in its long-term strategy. Wedbush subsequently downgraded CarMax to ‘Neutral’ from ‘Outperform’ and revised the price target to $54, down from $84.The new price target implies a downside of about 5% from the stock’s closing price on Wednesday.The "weak results" in Q2 underperformed expectations across "all key metrics," Wedbush said. &nbsp;These results are amplifying investors' concerns around management's ability to sustain market leadership and drive additional growth, according to the analyst. Wedbush is now eyeing a potential revision of its estimates for the company following the earnings call.KMX stock is down 46% this year and approximately 41% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-more-than-doubles-on-thursday/chDla07R34F">PepGen Stock More Than Doubles On Thursday – Check Out The New Price Targets On Wall Street</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of a CarMax dealership on April 10, 2025 in Santa Rosa, California. (Photo by Justin Sullivan/Getty Images)

Why Did CarMax Stock Tumble 24% Today?

Total vehicle sales of the company fell 4.1% year-over-year in the second quarter to 338,031 units, dragging revenue by 6% to $6.59 billion.

Bristol Myers Squibb (BMY) announced on Thursday that it will sell its moderate-to-severe plaque psoriasis drug, Sotyktu, at a discount of more than 80% to the current list price, starting in January 2026, to cash-paying patients.Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform. Eligible cash-paying U.S. patients with a Sotyktu prescription can buy the medicine through the platform, which offers shipping across all 50 states and Puerto Rico, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx">stated</a>. The platform will also provide patient support resources, it added.“We are taking a leading role in removing barriers, providing transparency and lowering out-of-pocket costs so patients in the United States can get the treatments they need – delivered directly to their door, wherever they are in the country,” CEO Christopher Boerner said.The announcement comes on the heels of President Trump <a href="https://stocktwits.com/news-articles/markets/equity/trump-to-issue-60-day-warning-letters-to-drugmakers-over-pricing/choL0IMRdGB">sending</a> letters to 17 drugmakers demanding that they lower drug prices in the U.S. to levels paid by other wealthy nations. The deadline for meeting the demand is on Monday, and the White House has warned of action against those who do not comply.Shares of the company traded 0.3% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BMY">BMY stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.In July, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://google.com/url?q=https://stocktwits.com/news-articles/markets/equity/bristol-myers-pfizer-to-offer-blood-thinning-drug-at-discount/ch8K8XqR5pI&amp;sa=D&amp;source=docs&amp;ust=1758807238695403&amp;usg=AOvVaw1vujNK93MaBpbwKU9R5Fiv">announced</a> that it will sell its blood thinner drug Eliquis to cash-paying patients for more than 40% discount to the current list price. Eliquis is a prescription medicine used in adults to reduce the risk of stroke and blood clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem. It is also used to treat blood clots in the veins of the legs or lungs, and reduce the risk of them occurring again after receiving treatment for blood clots.BMY stock is down approximately 22% this year and by about 12% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-rises-pre-market-over-fresh-hopes-of-deramiocel-approval-in-treating-genetic-disorder/chDlIyZR34h">Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026

Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform.

Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the stock.Hunterbrook <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/dexcom/">said</a> on Thursday that it has a short position on DXCM based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s flagship G7 continuous glucose monitor (CGM) device, “some diabetics are ending up in the ICU — or dead.” Hunterbrook Media is an investigative news outlet.The report stated that DexCom made an unauthorized design change to a key component of the G7 that internal studies showed was inferior by “every accuracy metric,” and the company sold the device anyway. This change was revealed during a surprise inspection by the U.S. Food and Drug Administration (FDA), the report stated.Several company executives left the company amid the FDA’s scrutiny and soaring complaints, the report said, while adding that patients are now returning to the G6 or switching to products from competitors, such as Abbott (ABT).Hunterbrook also stated that it has shared its probe with a senior official from the Health and Human Services (HHS) and requested that the FDA intervene. The firm also said that DexCom didn't respond to their requests for comments. The report named people who died or had to be hospitalized following wrong readings by the G7 device, including Billy Sosbe, who died in June, and Diana Bates Knight, who rushed her 6-year-old to the emergency, after the device misread her blood sugar by hundreds of points.“In Dexcom’s crisis, Abbott may see its chance. Our analysis of FDA data shows Dexcom receives more accuracy complaints than its market share predicts; Abbott receives significantly fewer,” Hunterbrook said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DXCM">DXCM</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_2_14_55_PM_png_eb2477f011.webp" alt="DXCM's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="578" height="57"><figcaption>DXCM's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that DexCom has proven technology and is leading in CGM.<stembedurl>https://stocktwits.com/CmonManGiveMeABreak/message/629329227</stembedurl>Another user, however, opined that the FDA might pull the G7 device from the market.<stembedurl>https://stocktwits.com/buddyopalosam/message/629325830</stembedurl>DXCM stock is down by 13% this year and by 5% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/equity/markets/kalvista-pharmaceuticals-hereditary-angioedema-drug-approved-in-eu-switzerland/chD3BkIR3TW">KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the DexCom logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

DexCom Stock Slumps 10% After Hunterbrook Media Investigation Raises Concerns About Its G7 Device

Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that some diabetics died after inaccurate readings from Dexcom’s G7  device.

Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s G7 continuous glucose monitor device, some diabetics are ending up in the ICU or dead.


Shares of GE Healthcare Technologies (GEHC) jumped 1% in the pre-market session on Thursday, following reports that the company is considering options, including the sale of a stake in its China unit.Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-18/ge-healthcare-is-said-to-explore-selling-stake-in-china-business?srnd=homepage-asia">reported</a> on Thursday, citing people familiar with the matter, that the U.S.medical technology company has been working with advisers to evaluate options for the business. A potential transaction may value the China assets at several billion dollars, the report said.However, no final decision has been made on the timing and size of a potential disposal, and considerations are preliminary, sources told Bloomberg. According to the report, China is the company’s second-largest market, with approximately 7,000 employees in the region. &nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GEHC">GEHC stock</a> fell from ‘bullish’ to’ neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:928/100;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_083008_png_caa300d3aa.webp" alt="GEHC's Sentiment Meter and Message Volume as of 7:49 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="928" height="100"><figcaption>GEHC's Sentiment Meter and Message Volume as of 7:49 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure>GE Healthcare was spun off from General Electric in 2023. It delivers advanced technologies, pharmaceutical diagnostics, and AI-powered tools for medical use. According to the company, it has over 200 imaging software applications and treats over a billion patients annually.In February, the company said that its revenue growth in the U.S. in 2024 was partially offset by continued market softness in China. For the second quarter, GE Healthcare reported adjusted earnings per share of $1.06, compared to $1 in the corresponding quarter of 2024, and revenue growth of 3% on a reported basis to $5 billion.GEHC stock is down 2% this year and approximately 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-89bio-stock-nearly-double-in-value/chDcHJIR3bc">Why Did 89bio Stock Nearly Double In Value Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of GE HealthCare Technologies Inc. in front of a screen showing the company's latest stock market chart on July 28, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GE Healthcare Reportedly Eyes Selling Stake In China Unit – More Details Inside

According to a Bloomberg report, no final decision has been made on the timing and size of a potential disposal, and considerations are preliminary.

Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that its experimental therapy significantly reduced symptoms of cat and birch allergies in late-stage trials, successfully meeting their key endpoints.In the <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-advances-allergy-pipeline-two-positive-phase-3-trials">trials</a>, patients with moderate to severe cat or birch allergies received direct instillation of either cat dander or birch pollen into the eyes, followed by a single subcutaneous administration of the allergen-blocking antibodies. The antibody blockers “significantly reduced” allergy symptoms compared to placebo, the company said.The company stated that the data from the studies will be presented at an upcoming medical conference and used to inform confirmatory late-stage trials. Both the cat and birch allergy programs are part of a broader allergy pipeline, which includes an ongoing study in adults with severe food allergy. Initial results from the food allergy trial have been encouraging, the company said on Monday.Regeneron Chief Scientific Officer George D. Yancopoulos stated on Monday that the company anticipates significant relief at the earliest assessment time point, which is expected to last over three months, in both our cat and birch allergy programs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. Shares of the company traded 1% higher in the pre-market session at the time of writing.Yancopoulos said that while millions suffer from the effects of allergies, most undergo allergy desensitization shots, often with disappointing results.“The purpose of these burdensome allergy shots is to try to build up allergen-blocking antibodies in the body. We wondered whether we could instead manufacture and directly provide allergen-blocking antibodies,” he said. “These recent Phase 3 allergen challenge trials, together with our earlier Phase 2 trials, provide compelling evidence that our first-in-class approach can have the potential to provide profound allergy relief – rapidly and durably after a single treatment – decreasing ocular, nasal and even asthma measures.”Regeneron noted that Birch pollen is one of the most common seasonal allergens in the U.S., affecting more than 10 million people, while cat allergy affects more than 20 million people. In the trials, patients received a combination of two antibody blockers or a placebo. Those who received the combination had fewer allergy symptoms, such as conjunctival redness.While additional late-stage trials in cat allergy are planned to begin in the first half of 2026, further late-stage development in birch allergy is expected to commence by the end of the year.REGN stock is down by 20% this year and by about 50% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/echostar-to-dell-17-billion-in-spectrum-assets-to-spacex/chwWH3JRdAD">EchoStar To Sell $17B In Spectrum Assets To SpaceX – Stock Rockets 40% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-experimental-therapy-reduced-symptoms-of-cat-birch-allergies-in-studies/chwWH37RdAw">directly on Stocktwits.</a>

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials

The company said that the antibody blockers “significantly reduced” allergy symptoms compared to a placebo in the trials. 

Regeneron Pharmaceuticals, Inc. (REGN) announced on Tuesday that the late-stage trial evaluating its investigational Cemdisiran monotherapy in adults with generalized myasthenia gravis (MG) yielded positive results.MG is a rare and chronic autoimmune disease where disrupted communication between nerves and muscles results in debilitating and potentially life-threatening muscle weakness. According to Regeneron, the disease impacts approximately 85,000 people in the U.S.Both Cemdisiran and the combination of Cemdisiran and the approved antibody Pozelimab (cemdi-poze) demonstrated improvements in activities of daily functioning such as talking, eating, breathing, vision, and mobility at week 24. Cemdisiran showed numerically better results across all generalized myasthenia gravis-specific outcomes, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-results-phase-3-trial-generalized">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of the company traded 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:576/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_26_at_12_07_06_PM_png_ed2effdb15.webp" alt="REGN's Sentiment Meter and Message Volume as of 12:07 p.m. ET on Aug. 26, 2025 | Source: Stocktwits" width="576" height="61"><figcaption>REGN's Sentiment Meter and Message Volume as of 12:07 p.m. ET on Aug. 26, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user believes that the stock may hit an all-time low soon.<stembedurl>https://stocktwits.com/Johny34211/message/626531477</stembedurl>The firm said that treatment-emergent adverse events (TEAEs) occurred in 69% of patients treated with Cemdisiran, 81% with cemdi-poze, and 77% with placebo. Serious TEAEs occurred in 3% of patients treated with Cemdisiran, 9% with cemdi-poze, and 14% with placebo, the company said. However, there were no treatment discontinuations due to adverse events through week 24 in the Cemdisiran arm, it added.The company also said that there were no deaths during the 24-week placebo-controlled portion of the trial. During the extension period, however, one death due to pneumonia occurred in the Cemdisiran arm, and one death due to septic shock occurred in the combination arm. Both deaths occurred in patients who were on concomitant immunosuppressive therapies, Regeneron said.The company now plans to apply for regulatory approval in the U.S. for Cemdisiran in the first quarter of 2026, pending discussions with the U.S. Food and Drug Administration (FDA).REGN stock is down by 18% this year and by 51% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-upgraded-nio-shares-with-price-target-hike/chsHCIGRdjA">This Chinese EV Stock Surged 8% Today And JPMorgan Just Upgraded The Shares With A Price Target Hike: Retail Eyes $10 By End Of Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon

The company now plans to apply for regulatory approval in the U.S. for Cemdisiran in the first quarter of 2026, pending discussions with the FDA.

Regeneron Pharmaceuticals, Inc. (REGN) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-applications-expanded-us">said</a> that the FDA will now decide on its submissions by the fourth quarter of 2025. The agency extended review time after determining that information provided since the completion of a recent inspection of a third-party manufacturer constituted a major amendment to each submission. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN</a> remained within the ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.Regeneron had submitted applications pertaining to the EYLEA HD prefilled syringe and another seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications. The delay, however, was <a href="https://stocktwits.com/news-articles/markets/equity/truist-cuts-price-target-on-regeneron-citing-near-term-investor-focus-on-eylea/chrHEcxRdeF">anticipated</a>, the company said.The firm said it resulted from observations during an FDA general site inspection at Catalent Indiana LLC, &nbsp;the filler for these regulatory applications.Novo Nordisk recently acquired Catalent. The firm submitted a response earlier this month to address the observations noted by the FDA. Regeneron said that the FDA will be able to act on its applications once the manufacturing issues are resolved. The FDA was previously expected to decide on the submissions by August 2025.EYLEA HD, however, remains available in the U.S. through vial administration and is approved to treat vision-threatening conditions that impact patients, such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).REGN stock is down by 17% this year and by about 51% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-says-tesla-model-yl-might-not-ever-come-to-us-markets/chsitLlRdhq">Elon Musk Said Tesla’s Model Y L Might Not Ever Come To US Markets – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions

The company said that the FDA will now decide on its submissions by the fourth quarter of 2025.

Humana Inc. (HUM) on Tuesday announced measures aimed at accelerating prior authorizations for care services, particularly outpatient services such as colonoscopies and CT scans.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HUM">Humana</a> trended within ‘bullish’ territory, accompanied by ‘high’ message volume.<figure class="image"><img style="aspect-ratio:624/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_22_at_9_02_08_AM_png_e240f6341d.webp" alt="HUM's Sentiment Meter and Message Volume as of 9 a.m. ET on July 22, 2025 | Source: Stocktwits" width="624" height="64"><figcaption>HUM's Sentiment Meter and Message Volume as of 9 a.m. ET on July 22, 2025 | Source: Stocktwits</figcaption></figure>The actions, the health insurance company said, will reduce the number of prior authorization requirements and make the process faster and more seamless while preserving the system of checks and balances that ensures the most high-cost, high-risk treatments are reviewed and approved before care is delivered.Humana CEO Jim Rechtin said that the current healthcare system is “too complex, frustrating, and difficult to navigate,” while emphasising the need to “do better.”“We are committed to reducing prior authorization requirements and making this process faster and more seamless to better support patients, caregivers, physicians, and healthcare organizations,” he added.By the start of 2026, Humana will eliminate approximately one-third of prior authorizations for outpatient services and provide a decision within one business day on at least 95% of all complete electronic prior authorization requests. Currently, Humana provides a decision within one business day on more than 85% of outpatient procedures.Humana will remove the authorization requirement for diagnostic services, including colonoscopies and transthoracic echocardiograms, as well as select CT scans and MRIs, by January 1, it said. &nbsp;The company also announced that it will launch a new gold card program in 2026, which will waive prior authorization requirements for certain items and services for providers who have a proven record of submitting coverage requests that meet medical criteria.Starting in 2026, the insurance provider will also report its prior authorization metrics to increase transparency. This includes prior authorization requests that are approved, denied, and approved after appeal, as well as the average time between submission and decision.A Stocktwits user opined that while Humana stock has fallen as hard as its peer, UnitedHealth, it does not share the same stigma as UNH.<stembedurl>https://stocktwits.com/Chartist0_0/message/621888373</stembedurl>However, it is essential to note that UNH shares have dropped 44% this year.Meanwhile, HUM stock is down 10% this year and approximately 41% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gm-mary-barra-highlights-efforts-to-mitigate-tariff-impact-in-future-after-q2-earnings-take-hit/ch8M15MR5tG">GM’s Mary Barra Highlights Efforts To Mitigate Tariff Impact After Q2 Earnings Take Hit: Retail Sees Levies Impact Consumer Spending</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana To Slash Red Tape Around Prior Authorization For Care Services By 2026: Retail Remains Optimistic

Humana CEO Jim Rechtin said that the current healthcare system is “too complex, frustrating, and difficult to navigate” while emphasising the need to “do better.”

Amplify ETF Trust - Amplify AI Powered Equity ETF

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

AIEQ
ETF Managers Group LLC - AI Powered Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest AIEQ News

AIEQETF Managers Group LLC - AI Powered Equity ETF